6533b81ffe1ef96bd1277adb
RESEARCH PRODUCT
Genomic landscape analyses in cervical carcinoma and consequences for treatment.
Henry Johannes GretenDominik DiefenbachThomas Efferthsubject
0301 basic medicineOncologymedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseDrug resistance030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineAnimalsHumansMicrobiomeCervixPapillomaviridaeRepurposingPharmacologybusiness.industryDNAGenomicsPrecision medicinePrognosis030104 developmental biologymedicine.anatomical_structureHuman genomeFemalebusinessChemoradiotherapydescription
Where we are on the road to ‘tailor-made’ precision medicine for drug-resistant cervical carcinoma? We explored studies about analyses of viral and human genomes, epigenomes and transcriptomes, DNA mutation analyses, their importance in detecting HPV sequences, mechanisms of drug resistance to established and targeted therapies with small molecule or therapeutic antibodies, to radiosensitivity and to chemoradiotherapy. The value of repurposing of old drugs initially approved for other disease indications and now considered for cervix cancer therapy is also discussed. The microbiome influences drug response and survival too. HPV genomic integration sites were less significant. Nomograms (Lee et al., 2013) even outperformed FIGO staging regarding prediction of five-year overall survival times. We conclude that there are still many loose threads to be followed up, before coherent conclusions for individualized therapy of drug-resistant cervical carcinoma can be drawn.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-10-01 | Current opinion in pharmacology |